Cullinan Oncology Inc SEC Filings

Cullinan Therapeutics director David D. Meek received a new stock option grant covering 25,319 shares of common stock. The option has an exercise price of $13.55 per share and represents a right to buy the company’s common stock directly.

According to the grant terms, the 25,319-share option will vest in full on the earlier of June 16, 2027 or the date of Cullinan Therapeutics’ next annual meeting, provided Meek continues to serve as a director through that vesting date. Following this grant, he holds stock options for 25,319 shares.

Cullinan Therapeutics director Stephen W. Webster received a stock option grant covering 25,319 shares of common stock. The option has an exercise price of $13.55 per share and was awarded as compensation, not an open-market purchase or sale. It vests in full on the earlier of June 16, 2027 or the company’s next annual meeting, contingent on his continued board service. Following this grant, Webster holds options for 25,319 underlying shares.

Cullinan Therapeutics director Andrew R. Allen received a grant of stock options covering 21,781 shares of common stock at an exercise price of $13.55 per share. These options vest in full on the earlier of June 16, 2027 or the company’s next annual meeting, subject to his continued board service.

Cullinan Therapeutics director Mary Thistle received a stock option grant covering 25,319 shares of common stock. The option has an exercise price of $13.55 per share and was granted at no cost to her.

The award vests in full on the earlier of June 16, 2027 or the company’s next annual meeting, as long as she continues serving as a director on that date. Following this grant, she holds options for 25,319 underlying shares.

Cullinan Therapeutics director Mittie Doyle received a new stock option grant. The award covers 21,781 shares of Common Stock at an exercise price of $13.55 per share. According to the terms, the option vests in full on the earlier of June 16, 2027 or the company’s next annual meeting, as long as she continues serving as a director.

Cullinan Therapeutics, Inc. reported the results of its Annual Meeting of Stockholders held on June 16, 2026. Stockholders elected two Class III directors to three-year terms. Nadim Ahmed received 37,519,241 votes for and 12,116,759 votes withheld, while Stephen Webster received 36,963,086 votes for and 12,672,914 votes withheld.

Stockholders also ratified KPMG LLP as the independent registered accounting firm for the fiscal year ending December 31, 2026, with 53,722,477 votes for, 36,815 against, and 3,138 abstentions. In an advisory vote, stockholders approved compensation for the named executive officers, with 48,536,734 votes for, 1,092,209 against, 7,057 abstentions, and 4,126,430 broker non-votes.

Cullinan Therapeutics reported new early-stage clinical data for its T cell engager programs CLN-978 and velinotamig in autoimmune diseases. In Phase 1 OUTRACE RA, two heavily pre-treated rheumatoid arthritis patients showed robust responses, including one DAS28-ESR remission with a disease score falling from 4.0 to 2.2 by week eight. Initial multi-dose data in systemic lupus erythematosus show a favorable safety profile and support a planned Phase 2a expansion in lupus nephritis, expected to start in early 2027.

For velinotamig, the first two refractory SLE patients treated in a Phase 1b/2a study in China experienced rapid drops in SLEDAI-2K scores (from 16 and 14 to 0 and 2 at week eight) and achieved complete renal response, with no CRS or ICANS observed. Cullinan plans further CLN-978 data in RA in Q3 2026 and SLE in Q4 2026, additional velinotamig data in Q4 2026, and a Phase 1/2a trial in autoimmune cytopenias beginning in Q1 2027.

Cullinan Therapeutics reported initial Phase 1 data for CLN‑978, a CD19xCD3 T cell engager, in treatment‑refractory systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) from its OUTRACE trials. As of May 15, 2026, 29 patients had been evaluated across multiple step‑up and multi‑dose cohorts.

In SLE, among 14 patients with at least four weeks of follow‑up, 10 (71%) achieved a ≥4‑point hSLEDAI reduction and 5 reached DORIS remission. Peripheral B cells fell by more than 80% in 14 of 17 patients, with half of those at target doses ≥20 µg reaching depletion below the limit of quantification.

In RA, 5 of 7 patients (71%) showed improved disease activity, including one DAS28‑ESR remission at a 30 µg target dose. Deep, dose‑dependent B cell depletion was observed in blood, lymph node and synovial tissue, while autoantibody levels declined without affecting protective vaccine titers.

Across 10, 20 and 30 µg target doses, CLN‑978 was described as well tolerated. Cytokine release syndrome occurred in 11 of 29 patients, mostly Grade 1 after the initial 10 µg dose; one Grade 3 case followed a 45 µg dose, leading to discontinuation of that cohort. No ICANS events were reported. Cullinan will also discuss these data, first RA multi‑dose results, and initial velinotamig data at an Immunology Day on June 10.

Cullinan Therapeutics reported initial data from its Phase 1 OUTRACE Program testing CLN-978 in treatment‑refractory rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). As of a January 14, 2026 cutoff, 14 patients were dosed across RA (5 patients) and SLE (9 patients) cohorts.

Single subcutaneous step‑up and target doses of 10, 20, or 30 micrograms produced robust B cell depletion. After 10 micrograms, 9 of 11 patients showed more than 75% B cell reduction versus baseline; after 20 micrograms, three of six fell below quantification, with the others showing reductions of 98.5%, 77%, and 64%.

Among patients with at least four weeks of follow‑up, four of five RA patients had lower DAS28‑ESR scores, including four of four improving from high disease activity to moderate activity or remission. Five of six SLE patients had SLEDAI score reductions greater than four points. CLN‑978 was described as well tolerated with a favorable safety profile, and dose escalation is ongoing. Updated data will be presented at the EULAR Congress in June 2026.